Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Abstract

Disease activity score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis.

Heidi Mäkinen, Hannu Kautiainen, Pekka Hannonen, Timo Möttönen, Markku Korpela, Marjatta Leirisalo-Repo, Reijo Luukkainen, Kari Puolakka, Anna Karjalainen and Tuulikki Sokka
The Journal of Rheumatology October 2007, 34 (10) 1987-1991;
Heidi Mäkinen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannu Kautiainen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pekka Hannonen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timo Möttönen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markku Korpela
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marjatta Leirisalo-Repo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reijo Luukkainen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kari Puolakka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Karjalainen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tuulikki Sokka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

OBJECTIVE: To examine the influence of components of the Disease Activity Score 28 (DAS28) [tender joint count (TJC), swollen joint count (SJC), patient's general health (GH), and erythrocyte sedimentation rate (ESR)] on the total DAS28 score, and overlapping of the 4 individual components in rheumatoid arthritis (RA) patients with low, moderate, or high disease activity. METHODS: The effect of each component was studied in the FIN-RACo trial patients at 6 months and in a "theoretical model," where each component of the DAS28 ranged as follows: TJC and SJC from 0 to 28, GH from 0 to 100, and ESR from 1 to 100, while the other 3 components were 0 (ESR1). Overlapping of the components was studied in the FIN-RACo trial patients at 6 months with low (DAS28 < or = 3.2), moderate (DAS28 > 3.2 and < or = 5.1), and high (DAS28 > 5.1) disease activity. The higher limit for overlapping was defined as the highest SJC in the low disease activity group, and the lower limit as the lowest SJC in the high disease activity group; the percentage of patients who fall between these limits represent overlapping in SJC. Overlapping was calculated similarly concerning TJC, ESR, and GH. RESULTS: ESR had the greatest effect on DAS28, followed by TJC, GH, and SJC, while in the "theoretical model" TJC had the greatest effect on the DAS28, followed by ESR, SJC, and GH. At 6 months, overlapping was present in 54%, 45%, 49%, and 31% of patients in SJC, TJC, GH, and ESR, respectively. CONCLUSION: In real-life patients, ESR had the greatest effect of the 4 components of DAS28 on the total DAS28 score. The values of the individual components of DAS28 overlap considerably among the 3 disease activity groups.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 34, Issue 10
1 Oct 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Disease activity score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis.
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Disease activity score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis.
Heidi Mäkinen, Hannu Kautiainen, Pekka Hannonen, Timo Möttönen, Markku Korpela, Marjatta Leirisalo-Repo, Reijo Luukkainen, Kari Puolakka, Anna Karjalainen, Tuulikki Sokka
The Journal of Rheumatology Oct 2007, 34 (10) 1987-1991;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Disease activity score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis.
Heidi Mäkinen, Hannu Kautiainen, Pekka Hannonen, Timo Möttönen, Markku Korpela, Marjatta Leirisalo-Repo, Reijo Luukkainen, Kari Puolakka, Anna Karjalainen, Tuulikki Sokka
The Journal of Rheumatology Oct 2007, 34 (10) 1987-1991;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire